Swiss medicines authority issues first approval for antimalarial drug for treatment of infants
Swissmedic gave a green light Tuesday for use of the medicine from Basel-based pharmaceutical company Novartis for treatment of babies with body weights between 2 and 5 kilograms (nearly 4½ to 11 pounds), which could pave the way for hard-hit African nations to follow suit in coming months.
Sigificance of infant-designed version of the medicine
The agency said that the decision is 'significant' in part because it's only the third time it has approved a treatment under a fast-track authorisation process, in coordination with the World Health Organization, to help developing countries access needed treatment.
The infant-designed version of the medicine has already been approved for other age groups, including older children. Quique Bassat, a malaria expert not affiliated with the Swiss review, said that the disease typically becomes frequent in most-affected areas after children reach 3 to 6 months of age, and the burden of malaria in very young children is 'relatively low' compared to older kids.
But access to such medicines is important to all, he said.'There is no doubt that any child of whichever age — and particularly very, very young ones or very light-weighted ones — require a treatment,' said Bassat, the director- general of the Barcelona Institute for Global Health, known as ISGlobal.
Up to now, antimalarial drugs designed for older children have been administered to small infants in careful ways to avoid overdose or toxicity, in what Bassat called a 'suboptimal solution' that the newly designed medicine could help rectify. 'This is a drug which we know is safe, we know works well, and therefore it will just be available as a new version for a specific age group,' he said.
Ruairidh Villar, a Novartis spokesperson, said that eight African countries took part in the assessment and are expected to approve the medicine within 90 days. The company said that it's planning on a rollout on a 'largely not-for-profit basis' in countries where malaria is endemic.
The mosquito-borne illness is the deadliest disease in Africa, whose 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to WHO. More than three-quarters of those deaths were among children.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
WHO recommends a twice-a-year injection for HIV prevention
The World Health Organization is now recommending that countries include a newly approved HIV drug for prevention, lenacapavir, as a tool in their efforts to fight HIV infections, especially for groups most at risk and in areas where the burden of HIV remains high. This landmark guidance, released at the 13th International AIDS Society Conference in Kigali on July 14 – as concern looms over funding for the global HIV fight – endorses the drug's use every six months, marking a pivotal shift from daily pills to long‑acting, needle‑delivered protection. What is Lenacapavir? Lenacapavir (brand names Sunlenca for treatment, Yeztugo for prevention) is a long‑acting capsid inhibitor that has redefined HIV prevention. Administered via injection just twice a year, it works by targeting the structural protein (capsid) of the HIV, blocking its ability to replicate in the body. Lenacapavir was approved in 2022 to treat certain HIV infections, and in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection against HIV. WHO's official recommendation Dr. Meg Doherty, director of WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, said in a news briefing, 'These new recommendations are designed for real-world use. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo WHO is working closely with countries and partners to support the implementation.' Doherty added, 'The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention. With that, we call it a strong recommendation with moderate to high certainty of the evidence.' The second recommendation in the guidelines is that rapid diagnostic tests, like at-home tests, can be used to screen someone for HIV when they are starting, continuing, or stopping long-acting medication to prevent infection, called pre-exposure prophylaxis, or PrEP. Health leaders, including WHO's Director‑General Dr. Tedros Adhanom Ghebreyesus, touted lenacapavir as 'the next best thing' to an HIV vaccine. This latest endorsement complements existing WHO‑approved prevention methods – daily oral PrEP, bi‑monthly cabotegravir injections, and the dapivirine vaginal ring. WHO also streamlined HIV testing protocols to support injectable PrEP uptake in community settings, pharmacies, and telehealth contexts. Why a twice‑yearly injection might prove to be a good shot Adherence and convenience: Daily pill demands consistency, which many at‑risk individuals struggle to maintain. Lenacapavir simplifies prevention to two clinic visits per year, helping sidestep barriers like stigma, pill fatigue, or limited healthcare access. Effectiveness: Purpose trial data speaks volumes: in one study, zero infections occurred among participants receiving lenacapavir, compared to significant infection rates in the pill‑based PrEP group. Equity and access: High‑risk populations – sex workers, LGBTQ+ individuals, people who inject drugs, incarcerated people, adolescents – stand to gain most from an easy‑to‑administer, long‑lasting prevention tool. What is HIV/AIDS? HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome). Within a few weeks of HIV infection, flu-like symptoms such as fever, sore throat, and fatigue can occur. Then the disease is usually asymptomatic until it progresses to AIDS. AIDS symptoms include weight loss, fever or night sweats, fatigue, and recurrent infections. There is no existing cure for AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease's progress as well as prevent secondary infections and complications. Vaccines for HIV are under trial, but no effective vaccine has been developed to date. In early 2025, the global fight against HIV/AIDS faced a significant setback with the United States of America's decision to halt foreign aid funding for HIV prevention and treatment programs. This move, part of a broader 90-day pause in US foreign development assistance, sent shockwaves through the international health community only a week ago, raising alarms about a potential resurgence of the epidemic. WHO's endorsement of twice‑yearly lenacapavir marks a transformative moment, especially amidst the looming concerns regarding the funding cuts. Gilead Sciences, maker of lenacapavir, recently announced that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead's pricing reflects only the cost of producing and delivering lenacapavir. Gilead Chairman and CEO Daniel O'Day said in a news release, 'We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available.' Peter Sands, executive director of the Global Fund, said in the news release, lenacapavir can 'fundamentally change the trajectory of the HIV epidemic,' but only if it reaches the people who need it most. As per him, 'Our ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required. This is a pivotal moment — not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most — whoever they are, and wherever they live.' If scaled equitably and thoughtfully, this intervention could reshape the landscape of HIV prevention, moving us closer to a world without AIDS. Actor Nargis Fakhri Reveals 9‑Day Water Fast Twice a Year to Get 'Snatched'
Time of India
4 hours ago
- Time of India
Can vaping cause cancer? Top NYC doctor responds
Vaping is increasingly becoming popular, especially among adolescents. Some consider it a safer alternative to conventional cigarettes. Its popularity among youngsters is raising concerns about its safety. Tired of too many ads? go ad free now Whether vaping has any health risks, particularly if it has the potential to cause cancer, is a growing concern. Dr. Tim Tiutan, a New York City-based board-certified internal medicine physician who treats cancer patients, has weighed in on the issue. Before we dive into that, let's understand what vaping is. What is vaping Vaping involves inhaling an aerosol (not water vapor) produced by an electronic cigarette (e-cigarette) or similar device called a vape. These devices heat a liquid, often called e-liquid or vape juice, which usually contains nicotine, flavorings, and other chemicals, turning it into an aerosol that can be inhaled into the lungs. Vaping is similar to smoking a cigarette, but it does not involve burning tobacco. Vapes come in all shapes and sizes. These include e-pens, e-pipes, e-hookah, and e-cigars. Despite their variety, they contain the same basic components. Battery Heating element Place to hold e-liquid (such as a cartridge or pod) According to the American Lung Association, the following toxic chemicals and metals have all been found in e-cigarettes. Nicotine: It is a highly addictive substance that negatively affects adolescent brain development Propylene glycol: A common food additive, also used to make things like antifreeze, paint solvent, and artificial smoke in fog machines Carcinogens: These are chemicals known to cause cancer, including acetaldehyde and formaldehyde Acrolein: It is a herbicide primarily used to kill weeds. This chemical can cause irreversible lung damage Diacetyl: A chemical linked to a lung disease called bronchiolitis obliterans, aka 'popcorn lung' Diethylene glycol: A toxic chemical used in antifreeze that is linked to lung disease Heavy metals such as nickel, tin, lead Cadmium: A toxic metal found in traditional cigarettes that causes breathing problems and other illnesses Benzene: A volatile organic compound (VOC) found in car exhaust Ultrafine particles that can be inhaled deep into the lungs So, it's not just vapor one is inhaling. Hidden dangers of vaping Though vaping is often assumed to be a safer alternative to traditional smoking, Dr. Tiutan warns that the substances used in it are far from harmless. 'I don't have to tell you that inhaling random unregulated substances can cause lung damage and heart disease,' the doctor said in a shared on Instagram. Tired of too many ads? go ad free now He also quoted studies and added, 'Early studies also suggest vaping may increase cancer risk.' Vaping releases oxygen-free radicals that may cause DNA damage. He added that various compounds commonly found in vape liquid, like heavy metals and polycyclic aromatic hydrocarbons, can wreak havoc on health. 'I think there's so much more harm we've yet to discover so quit vaping,' he said. Top foods to prevent lung cancer A recent has found that vaping is more dangerous than traditional cigarettes. 'We found that these disposable devices have toxins already present in the e-liquid, or they're leaching quite extensively from their components into e-liquids and ultimately transferred to the smoke,' the researchers said. 'Our study highlights the hidden risk of these new and popular disposable electronic cigarettes — with hazardous levels of neurotoxic lead and carcinogenic nickel and antimony — which stresses the need for urgency in enforcement,' they confirmed.
Hans India
5 hours ago
- Hans India
State launches first-of-its-kind DigiLocker-based nurse registration system
Bengaluru: Forthe first time in the country, a special DigiLocker-based technology developed by the Karnataka State Nursing Council for the registration of nurses is being implemented, state Medical Education Minister Sharanprakash Patil said on Monday. In a statement, he said the new technology, which facilitates the issuance of registration certificates through Aadhaar-based DigiLocker e-KYC, will be officially launched on July 15 by Chief Minister Siddaramaiah. 'The system has been developed in collaboration with UIDAI, C-eG, Rajiv Gandhi University of Health Sciences (RGUHS) and the Karnataka State Nursing Examination Board,' he said. According to Patil, with this technology, the Karnataka State Nursing Council can directly retrieve personal data, address, photo, and other details of nurses from the Aadhaar server through e-KYC. Previously, nursing candidates from various districts had to travel to the Council's central office in Bengaluru for registration. 'Nurses from within and outside the state were forced to spend thousands of rupees on food and accommodation solely for registration purposes. They also had to wait in long queues at the Bengaluru office. Many women, pregnant women and new mothers faced considerable inconvenience,' the minister said, adding that the implementation of this new technology puts an end to all these issues. For the first time in India, the Aadhaar and DigiLocker-based e-KYC system is being used to eliminate the difficulties faced by nurses coming from all corners of the state and other states to register with the Karnataka State Nursing Council, he added.
